13F Holdings
中文EN

Spruce Street Capital LP

NEW YORK NY · SEC CIK 0002050194

2026Q22026Q1 9 earlier quarters 🔒
$509.68M2026Q2 reported value
30Positions
70.2%Top 10 weight · largest 11.5%
3 / 3New / sold out
Reported value over time$509.68M2026Q2
26Q126Q2

All 11 quarters on paid plans 🔒

Top 10 holdings % of portfolio

KNSA 11.5%
RLAY 11.0%
LBRX 8.8%
RLMD 8.7%
ANRO 7.0%
DNTH 6.8%
ALKS 5.6%
SVRA 4.2%
PCVX 3.5%
ELVN 3.3%

2026Q2 top buys estimated at quarter-end value

IFRX New+$11.99M
ALKS Added+$11.84M
KNSA Added+$10.04M
ZLAB New+$5.30M
ACHV New+$4.81M

2026Q2 top sells estimated at quarter-end value

CENTESSA PHARMAC Sold out-$19.46M
KALVISTA PHARMAC Sold out-$18.07M
MAZE Sold out-$5.97M
DNTH Reduced-$1.80M

2026Q2 holdings click a header to sort

Export CSV 🔒
TickerNameValue ▼WeightSharesShare changeChangeEst. flowAction
KNSA KINIKSA PHARMACEUTICALS INTL $58.71M11.52%918,070 157,00720.6% $10.04M Added
RLAY RELAY THERAPEUTICS INC $55.83M10.95%2,984,125 00.0% — Unchanged
LBRX LB PHARMACEUTICALS INC $44.66M8.76%1,376,159 00.0% — Unchanged
RLMD RELMADA THERAPEUTICS INC $44.23M8.68%6,391,328 129,2142.1% $894,161 Added
ANRO ALTO NEUROSCIENCE INC $35.71M7.01%1,353,047 27,8372.1% $734,618 Added
DNTH DIANTHUS THERAPEUTICS INC $34.59M6.79%354,816 -18,458-4.9% -$1.80M Reduced
ALKS ALKERMES PLC $28.50M5.59%543,876 225,88471.0% $11.84M Added
SVRA SAVARA INC $21.27M4.17%3,452,576 69,4012.1% $427,510 Added
PCVX VAXCYTE INC $17.79M3.49%306,047 60,33824.6% $3.51M Added
ELVN ENLIVEN THERAPEUTICS INC $16.70M3.28%329,006 00.0% — Unchanged
ENTA ENANTA PHARMACEUTICALS INC $15.87M3.11%1,088,731 156,13316.7% $2.28M Added
CATX PERSPECTIVE THERAPEUTICS INC $12.60M2.47%3,693,931 1,066,82440.6% $3.64M Added
IFRX INFLARX NV $11.99M2.35%5,352,198 5,352,198— $11.99M New
SRZN SURROZEN INC $11.21M2.20%432,040 00.0% — Unchanged
ALMS ALUMIS INC $11.05M2.17%392,574 00.0% — Unchanged
IPSC CENTURY THERAPEUTICS INC $9.94M1.95%4,059,054 00.0% — Unchanged
NERV MINERVA NEUROSCIENCES INC $9.19M1.80%1,655,500 00.0% — Unchanged
SABS SAB BIOTHERAPEUTICS INC $8.57M1.68%2,198,502 00.0% — Unchanged
— AN2 THERAPEUTICS INC $8.04M1.58%1,661,073 00.0% — Unchanged
ERAS ERASCA INC $7.74M1.52%422,543 00.0% — Unchanged
IKT INHIBIKASE THERAPEUTICS INC $7.27M1.43%3,581,603 00.0% — Unchanged
— RESEARCH ALLIANCE CORP III $5.35M1.05%500,000 500,000— — First reported
HLXC HELIX ACQUISITION CORP III $5.32M1.04%500,000 00.0% — Unchanged
ZLAB ZAI LAB LTD $5.30M1.04%279,110 279,110— $5.30M New
ACHV ACHIEVE LIFE SCIENCE INC $4.81M0.94%736,637 736,637— $4.81M New
LXEO LEXEO THERAPEUTICS INC $4.32M0.85%928,593 00.0% — Unchanged
ALEC ALECTOR INC $4.22M0.83%2,101,068 00.0% — Unchanged
— LEONABIO INC $3.62M0.71%393,701 00.0% — Unchanged
CRVS CORVUS PHARMACEUTICALS INC $3.46M0.68%231,585 00.0% — Unchanged
— JATT II ACQUISITION CORP $1.82M0.36%160,000 160,000— — First reported
— CENTESSA PHARMACEUTICALS $00.00%0 -489,849-100.0% -$19.46M Sold out
— KALVISTA PHARMACEUTICALS $00.00%0 -897,681-100.0% -$18.07M Sold out
MAZE MAZE THERAPEUTICS INC $00.00%0 -200,000-100.0% -$5.97M Sold out